Latest Morning Briefing Stories
The deal was struck in August and its liability clauses have not previously been reported, according to Reuters and CNBC. Other vaccine news is on the trials being run by Novavax and Sanofi, and more. And also: New York’s decision to review vaccines.
He tucked the news into a speech about his health care vision but didn’t provide many details. It’s possible the cards may be intended to help seniors pay for the COVID vaccine, which reportedly might not be covered by Medicare.
President Donald Trump announced the final rule that clears the way for states to import cheaper medicines from Canada while outlining his “America First Health Plan” Thursday.
Opinion writers weigh in on these pandemic issues and others as the U.S. death toll passes 200,000.
With no clinical trials underway, a COVID-19 vaccine for children is unlikely before the fall of 2021. Other news stories report the latest on vaccine development by Sanofi, Merck and AstraZeneca.
“That has to be approved by the White House. We may or may not approve it. That sounds like a political move,” President Donald Trump said about a draft FDA plan to apply tougher safety and efficacy requirements for emergency use approval of a COVID-19 vaccine.
Editorial writers focus on these pandemic topics and others.
Four COVID-19 experimental vaccines are now in Phase 3 of clinical trial testing, but Johnson & Johnson’s candidate is the only one that could be delivered in one shot instead of two.
Draft guidelines submitted by the FDA to the White House propose standards for authorizing emergency use of a COVID-19 vaccine that match ones set for regular vaccine approval, The Washington Post reported. The agency’s move aims to reassure the public about vaccine safety and lowers the chances that one might be cleared before the Nov. 3 election.
Missing from participation are the U.S., China and Russia. Other vaccine news including developments in Russia and China.
Also in the news: the price of insulin versus other drugs; Legend Biotech; Keytruda; and Perdue Pharma CEO Craig Landau.
The latest forecast from President Donald Trump came Friday when he said, “I think distribution will go even quicker than most people think.” Complex logistics challenge that timeline, public health and vaccine experts say.
In a letter Wednesday, 11 state officials asked the company to “responsibly commit to being a part of our nation’s recovery from COVID-19, both medically and economically, by repricing this drug more affordably.”
Rep. Andy Harris (R-Md.) is on the data and safety monitoring committee for the drug aviptadil. The five-term congressman’s membership on the board is unusual; former FDA chief Scott Gottlieb told Politico he hadn’t heard of a member of Congress sitting on such a committee for any drug. Surgeon General Jerome Adams and Dr. Anthony Fauci also make headlines.
Companies typically share these plans after studies are complete, but both companies hope to earn the trust of the public and scientists.
More moderate Democrats expressed concerns about the progressive labeling of the bill and failure to pass a relief bill.
President Donald Trump announced the second round of aid for farmers during a reelection rally in Wisconsin. More details are expected today. Other Trump campaign news covers drug importation and pricing, the United Nations and opioids.
Editorial pages focus on these pandemic topics and others.
Eli Lilly is developing the monoclonal antibody drug with biotechnology firm AbCellera.
Researchers at the University of Florida collected three 3-hour air samples from a room on a dedicated COVID-19 ward that was well ventilated, with six air exchanges per hour and triple-filter treatment of air returned to the room, CIDRAP reports.